| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/18/2008 | CA2359640C Topical sprays |
| 11/18/2008 | CA2359338C Bacillus subtilis takemi and use thereof |
| 11/18/2008 | CA2358487C Use of phanquinone for the treatment or prevention of memory impairment |
| 11/18/2008 | CA2358054C Cyanocobalamin (vitamin b12) treatment in allergic disease |
| 11/18/2008 | CA2352430C New pharmaceutical composition and the process for its preparation |
| 11/18/2008 | CA2352275C Il-5 inhibiting 6-azauracil derivatives |
| 11/18/2008 | CA2344166C Compositions of .beta.-glucans and specific igiv |
| 11/18/2008 | CA2344057C Treatment of persistent pain |
| 11/18/2008 | CA2343284C Topical application products |
| 11/18/2008 | CA2343116C Methods and compositions for increasing intestinal absorption of fats |
| 11/18/2008 | CA2341366C Micronised pharmaceutical compositions |
| 11/18/2008 | CA2340912C Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof |
| 11/18/2008 | CA2340417C Methods for forming regional tissue adherent barriers and drug delivery systems |
| 11/18/2008 | CA2339190C Compressed compositions comprising clarified xanthan gum |
| 11/18/2008 | CA2338721C New cofactors for methyltransferases |
| 11/18/2008 | CA2336945C Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| 11/18/2008 | CA2335154C Desformoterol and process for its preparation |
| 11/18/2008 | CA2333442C Spray composition |
| 11/18/2008 | CA2331187C Water soluble azoles as broad-spectrum antifungals |
| 11/18/2008 | CA2326809C Solid, quick dissolving cetirizine formulations |
| 11/18/2008 | CA2321658C Disinfecting composition |
| 11/18/2008 | CA2320822C Substituted isoindolones and their use as cyclic gmp modulators in medicaments |
| 11/18/2008 | CA2318184C Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative as selective endothelin antagonists |
| 11/18/2008 | CA2316539C Sustained-release pharmaceutical composition |
| 11/18/2008 | CA2316298C Fat blend |
| 11/18/2008 | CA2314564C Phosphonocephem derivatives, their production and use |
| 11/18/2008 | CA2314326C Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
| 11/18/2008 | CA2305802C Amide derivatives or salts thereof |
| 11/18/2008 | CA2301899C Agent with an antidepressant activity |
| 11/18/2008 | CA2301725C Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
| 11/18/2008 | CA2301646C Pharmaceutical suspension comprising nevirapine hemihydrate |
| 11/18/2008 | CA2298057C Nucleotide analog compositions |
| 11/18/2008 | CA2296725C Polyhydroxybutylpyrazines, their preparation and medicines containing them |
| 11/18/2008 | CA2296492C Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine |
| 11/18/2008 | CA2293706C N-substituted urea inhibitors of farnesyl-protein transferase |
| 11/18/2008 | CA2290315C Method for producing dispersible sterol and stanol compounds |
| 11/18/2008 | CA2287781C Methods for measuring cellular proliferation and destruction rates in vitro and in vivo |
| 11/18/2008 | CA2281420C Preparation of pharmaceutically-active granules |
| 11/18/2008 | CA2277791C Oxcarbazepine film-coated tablets |
| 11/18/2008 | CA2264941C Use of a combination of an atypical antipsychotic and a serotonin reuptake inhibitor for treatment of psychosis |
| 11/18/2008 | CA2259764C Pharmaceutical compositions containing mupirocin |
| 11/18/2008 | CA2259430C Water miscible erythromycin solutions |
| 11/18/2008 | CA2249361C Enhancement of microbial colonisation of the gastrointestinal tract |
| 11/18/2008 | CA2248753C Use of olanzapine for treating excessive aggression |
| 11/18/2008 | CA2247115C Inhibition of selectin binding |
| 11/18/2008 | CA2245125C Use of one extract of at least one rosaceae plant |
| 11/18/2008 | CA2230516C Pyrimidine derivatives |
| 11/18/2008 | CA2205112C Method and composition for treating mammalian diseases caused by inflammatory response |
| 11/18/2008 | CA2201855C Preventive or remedy for diseases caused by abnormalities in cartilage tissues |
| 11/18/2008 | CA2143752C Method of preventing nmda receptor-mediated neuronal damage |
| 11/18/2008 | CA2133587C Compounds having selectivity for retinoid x receptors |
| 11/18/2008 | CA2107884C Use of vasoactive intestinal peptide (vip) to induce temporary paralysis of the gastrointestinal tract |
| 11/18/2008 | CA1341585C Recombinant retroviruses |
| 11/14/2008 | CA2685748A1 Azido purine nucleosides for treatment of viral infections |
| 11/13/2008 | WO2008137960A1 Nasal administration of benzodiazepines |
| 11/13/2008 | WO2008137930A1 TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
| 11/13/2008 | WO2008137923A2 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| 11/13/2008 | WO2008137917A1 Method of treating bacterial infections with antibacterial formulations |
| 11/13/2008 | WO2008137891A1 Lung injury treatment |
| 11/13/2008 | WO2008137868A1 Detecting succinylacetone |
| 11/13/2008 | WO2008137803A1 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
| 11/13/2008 | WO2008137794A1 Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 11/13/2008 | WO2008137793A1 Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists |
| 11/13/2008 | WO2008137787A2 Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| 11/13/2008 | WO2008137780A2 Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
| 11/13/2008 | WO2008137779A2 Novel macrocyclic inhibitors of hepatitis c virus replication |
| 11/13/2008 | WO2008137778A2 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia |
| 11/13/2008 | WO2008137770A1 Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 11/13/2008 | WO2008137753A2 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| 11/13/2008 | WO2008137747A1 Nanoemulsion therapeutic compositions and methods of using the same |
| 11/13/2008 | WO2008137740A1 Fulvene and fulvalene analogs and their use in treating cancers |
| 11/13/2008 | WO2008137717A1 Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| 11/13/2008 | WO2008137705A1 Prevention of cancers by immunization |
| 11/13/2008 | WO2008137699A2 Topical formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice with multiple modes of action |
| 11/13/2008 | WO2008137692A1 Treatment of synucleinopathies |
| 11/13/2008 | WO2008137658A1 Otitis externa |
| 11/13/2008 | WO2008137630A1 Use of hdac inhibitors for the treatment of gastrointestinal cancers |
| 11/13/2008 | WO2008137622A2 Aminopyrimidines useful as kinase inhibitors |
| 11/13/2008 | WO2008137621A1 Aminopyrimidines useful as kinase inhibitors |
| 11/13/2008 | WO2008137619A2 Thiazoles and pyrazoles useful as kinase inhibitors |
| 11/13/2008 | WO2008137605A1 Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors |
| 11/13/2008 | WO2008137600A1 Methods for measuring platelet reactivity of individuals treated with drug eluting stents |
| 11/13/2008 | WO2008137496A1 Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same |
| 11/13/2008 | WO2008137488A1 Methods for controlling inflammatory and immunological diseases |
| 11/13/2008 | WO2008137476A1 Arylthioacetamide carboxylate derivatives as fkbp inhibitors for the treatment of neurological diseases |
| 11/13/2008 | WO2008137474A1 Morphinan compounds |
| 11/13/2008 | WO2008137461A1 Naphthyl(ethyl) acetamides |
| 11/13/2008 | WO2008137446A1 Methods and compositions for the treatment of respiratory disease |
| 11/13/2008 | WO2008137444A1 N-halogenated amino acid formulations with anti-inflammatory compounds |
| 11/13/2008 | WO2008137436A1 [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
| 11/13/2008 | WO2008137435A1 [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| 11/13/2008 | WO2008137420A1 Honokiol analogs and their use in treating cancers |
| 11/13/2008 | WO2008137408A1 Pyrazole inhibitors of wnt signaling |
| 11/13/2008 | WO2008137318A1 Compositions and methods for treating disorders associated with salt or fluid retention |
| 11/13/2008 | WO2008137270A1 Methods of diagnosing and monitoring of npy y5 based disorders |
| 11/13/2008 | WO2008137236A2 Treatment of age-related macular degeneration using inhibitors of complement factor d |
| 11/13/2008 | WO2008137176A1 Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
| 11/13/2008 | WO2008137149A1 Diabetic wound healing |
| 11/13/2008 | WO2008137148A2 Methods and compositions for treating pulmonary hypertension |
| 11/13/2008 | WO2008137139A1 Gamma secretase modulators |